{
      "StudyFieldsResponse": {
            "APIVrs": "1.01.05",
            "DataVrs": "2022:10:06 23:25:58.836",
            "Expression": "mesenchymal NurOwn",
            "NStudiesAvail": 430108,
            "NStudiesFound": 4,
            "MinRank": 1,
            "MaxRank": 1000,
            "NStudiesReturned": 4,
            "FieldList": [
                  "DesignTimePerspective",
                  "DesignWhoMasked",
                  "DetailedDescription",
                  "DispFirstPostDate",
                  "DispFirstPostDateType",
                  "DispFirstSubmitDate",
                  "DispFirstSubmitQCDate",
                  "EligibilityCriteria",
                  "EnrollmentCount",
                  "EnrollmentType",
                  "EventGroupDeathsNumAffected",
                  "EventGroupDeathsNumAtRisk",
                  "EventGroupDescription",
                  "EventGroupId",
                  "EventGroupOtherNumAffected",
                  "NCTId"
            ],
            "StudyFields": [
                  {
                        "Rank": 1,
                        "DesignTimePerspective": [],
                        "DesignWhoMasked": [],
                        "DetailedDescription": [
                              "An open-label study with a single treatment arm involving 20 participants with progressive MS at multiple investigational study sites. After providing informed consent, participants meeting the inclusion and exclusion criteria will be randomized and approximately 4 weeks later will undergo a bone-marrow aspiration (BMA). Each participants will receive three Intrathecal cell transplantations within 16 weeks and will be followed for 12 weeks for safety and efficacy."
                        ],
                        "DispFirstPostDate": [],
                        "DispFirstPostDateType": [],
                        "DispFirstSubmitDate": [],
                        "DispFirstSubmitQCDate": [],
                        "EligibilityCriteria": [
                              "Inclusion Criteria:\n\nMales and females ages 18 to 65 years old, inclusive, at the Screening Visit.\nClinical diagnosis of Progressive MS (Primary and Secondary) based on the 2017 revised MacDonald Criteria and confirmation by the Investigator that the disease has entered the progressive stage for at least 6 months prior to enrollment.\nNo evidence of clinical MS relapse or high dose pulse corticosteroid treatment within 6 months prior to screening\nDisability status at screening with an Expanded Disability Status Scale (EDSS) 3.0-6.5, inclusive.\nAble to walk 25 feet in 60 seconds or less.\nStable dose of non-excluded MS Disease Modifying Therapy for at least 6 months prior to Screening Visit (Visit 1).\n\nExclusion Criteria:\n\nPrior stem cell therapy of any kind.\nActive participation in any other MS interventional study or use of unapproved MS investigational therapy within 90 days prior to the Screening Visit (Visit 1).\nInability to lie flat for the duration of intrathecal cell transplantation and/or bone marrow biopsy, or inability to tolerate study procedures for any other reason.\nHistory of clinically significant autoimmune disease (excluding thyroid disease) that may confound study results, myelodysplastic or myeloproliferative disorder, leukemia or lymphoma, whole body irradiation, hip fracture, or severe scoliosis.\nAny unstable clinically significant medical condition other than multiple sclerosis (e.g., within six months of Screening Visit (Visit 1), had myocardial infarction, angina pectoris, and/or congestive heart failure), treatment with anticoagulants that, in the opinion of the investigator, would compromise the safety of participants.\nAny history of malignancy within the previous 5 years, except for non-melanoma localized skin cancers (with no evidence of metastasis, significant invasion, or reoccurrence within three years of Screening Visit (Visit 1)).\nSerum aspartate aminotransferase (AST) or alanine aminotransferase (ALT) value >3.0 times the upper normal limit.\nSerum creatinine value >2.0 times the upper normal limit.\nPositive test for Hepatitis B (HBV; surface antigen (HBsAg) and antibodies to core antigen (IgG and IgM anti-HBc)), Hepatitis C (HCV), or human immunodeficiency virus (HIV) 1 and 2.\nCurrent use of immunosuppressant medication or use of such medication within 6 months of study enrollment (aside from Rituximab or other approved B-cell immunotherapy). Alemtuzumab (Lemtrada), Cladribine (NDA submitted), Natalizumab (Tysabri), S1P modulators (Gilenya) are excluded for safety reasons due to the known risk of systemic autoimmune disease, malignancy, opportunistic infections, and cardiovascular toxicity associated with these therapies, as well as theoretical effects on MSC-NTF cell homing and migration, that may be associated with Natalizumab and/or S1P modulators (Gilenya).\nAny history of acquired or inherited immune deficiency syndrome.\nAny history of either substance abuse within the past year, or unstable psychiatric disease according to the Investigator's judgment.\nPregnant women or women currently breastfeeding.\nSubjects for whom MRI is contraindicated (i.e., have a pacemaker or other metallic implanted device, or are unable to remain in the machine for period of time needed to acquire a scan."
                        ],
                        "EnrollmentCount": [
                              "20"
                        ],
                        "EnrollmentType": [
                              "Actual"
                        ],
                        "EventGroupDeathsNumAffected": [],
                        "EventGroupDeathsNumAtRisk": [],
                        "EventGroupDescription": [],
                        "EventGroupId": [],
                        "EventGroupOtherNumAffected": [],
                        "NCTId": [
                              "NCT03799718"
                        ]
                  },
                  {
                        "Rank": 2,
                        "DesignTimePerspective": [],
                        "DesignWhoMasked": [
                              "Participant",
                              "Care Provider",
                              "Investigator",
                              "Outcomes Assessor"
                        ],
                        "DetailedDescription": [
                              "Neurotrophic factors (NTFs) are potent survival factors for embryonic, neonatal, and adult neurons and are considered potential therapeutic candidates for ALS. Delivery of multiple NTFs to the immediate environment of afflicted neurons in ALS patients is expected to improve their survival and thus slow down disease progression and alleviate symptoms. NTF-secreting mesenchymal stromal cells (MSC-NTF cells) are a novel cell-therapeutic approach aimed at effectively delivering NTFs directly to the site of damage in ALS patients.\n\nParticipants meeting the inclusion and exclusion criteria will be randomized and will undergo bone-marrow aspiration. MSC of the participants randomized to the treatment group will be induced into MSC-NTF cells. Participants will undergo a total of three intrathecal (IT) transplantations with NurOwn\u00ae (MSC-NTF cells) or matching placebo at three bi-monthly intervals"
                        ],
                        "DispFirstPostDate": [
                              "October 5, 2021"
                        ],
                        "DispFirstPostDateType": [
                              "Actual"
                        ],
                        "DispFirstSubmitDate": [
                              "October 3, 2021"
                        ],
                        "DispFirstSubmitQCDate": [
                              "October 3, 2021"
                        ],
                        "EligibilityCriteria": [
                              "Inclusion Criteria:\n\nALS diagnosed as possible, laboratory-supported probable, probable, or definite as defined by revised El Escorial criteria.\nHaving onset of ALS disease symptoms, including limb weakness within 24 months at the Screening Visit.\nALSFRS-R \u2265 25 at the screening Visit.\nUpright slow vital capacity (SVC) measure \u2265 65% of predicted for gender, height, and age at the screening Visit.\nRapid progressors\nParticipants taking a stable dose of Riluzole are permitted in the study\nCitizen or permanent resident of the United States or Canadian citizen able to travel to a US site for all follow-up study visits\n\nExclusion Criteria:\n\nPrior stem cell therapy of any kind\nHistory of autoimmune or other serious disease (including malignancy and immune deficiency) that may confound study results\nCurrent use of immunosuppressant medication or anticoagulants (per Investigator discretion)\nExposure to any other experimental agent or participation in an ALS clinical trial within 30 days prior to Screening Visit\nUse of RADICAVA (edaravone injection) within 30 days of screening or intent to use edaravone at any time during the course of the study including the follow up period\nUse of non-invasive ventilation (BIPAP), diaphragm pacing system or invasive ventilation (tracheostomy)\nFeeding tube\nPregnant women or women currently breastfeeding"
                        ],
                        "EnrollmentCount": [
                              "263"
                        ],
                        "EnrollmentType": [
                              "Actual"
                        ],
                        "EventGroupDeathsNumAffected": [],
                        "EventGroupDeathsNumAtRisk": [],
                        "EventGroupDescription": [],
                        "EventGroupId": [],
                        "EventGroupOtherNumAffected": [],
                        "NCTId": [
                              "NCT03280056"
                        ]
                  },
                  {
                        "Rank": 3,
                        "DesignTimePerspective": [],
                        "DesignWhoMasked": [
                              "Participant",
                              "Care Provider",
                              "Investigator"
                        ],
                        "DetailedDescription": [
                              "The MSC-NTF cell therapy (NurOwn\u2122) is based on transplantation of autologous bone marrow derived mesenchymal stromal cells (MSC), which are enriched from the patients' own bone marrow, propagated ex vivo and induced to secrete NTFs. The autologous MSC-NTF cells are back-transplanted into the ALS patient into the sites of damage, the spinal cord and the muscles.\n\nNTFs are potent survival factors for embryonic, neonatal, and adult neurons and are considered potential therapeutic candidates for ALS. Delivery of appropriate NTFs to the immediate environment of afflicted neurons in ALS patients is expected to improve their survival and thus slow down disease progression and alleviate symptoms.\n\nPrevious open-label clinical trials have shown that MSC-NTF cells treatment was well tolerated and appears to be generally safe. Some initials indications of clinical benefit were also observed in some patients.\n\nThis multi-center, randomized, double blind, placebo controlled study will evaluate the safety and efficacy of a single combined intramuscular and intrathecal administration of MSC-NTF cells in early-stage ALS patients. Patients will be followed for approximately three months before transplantation with their autologous MSC-NTF cells or placebo. During this period of time, patient bone-marrow will be harvested and mesenchymal stromal cells will be isolated and expanded. Following treatment patients will be followed for a total of six months at monthly visits."
                        ],
                        "DispFirstPostDate": [
                              "July 18, 2018"
                        ],
                        "DispFirstPostDateType": [
                              "Actual"
                        ],
                        "DispFirstSubmitDate": [
                              "July 15, 2018"
                        ],
                        "DispFirstSubmitQCDate": [
                              "July 15, 2018"
                        ],
                        "EligibilityCriteria": [
                              "Inclusion Criteria\n\nMales and females ages 18 to 75 years old, inclusive.\nALS diagnosed as possible, laboratory-supported probable, probable, or definite as defined by revised El Escorial criteria.\nDisease onset, as defined by first reported occurrence of symptomatic weakness, spasticity, or bulbar symptoms, of more than 12 months and less than or equal to 24 months.\nCurrent disease symptoms must include limb weakness.\nALSFRS-R \u226530 at the Screening Visit.\nUpright slow vital capacity (SVC) measure \u226565% of predicted for gender, height, and age at the Screening Visit.\nSubjects must be taking a stable dose of riluzole for at least 30 days prior to enrolment or not be on riluzole, and not have been on it for at least 30 days prior to enrolment (riluzole-na\u00efve subjects are permitted in the study).\nCapable of providing informed consent and willing and able to follow study procedures, including willingness to undergo lumbar puncture.\nGeographic accessibility to the study site and willingness and ability to comply with follow-up.\nWomen of child-bearing potential must agree not to become pregnant for the duration of the study. Women must be willing to consistently use two forms of contraceptive therapy throughout the course of the trial, and undergo a pregnancy test one week before bone marrow aspiration. Men must be willing to consistently use two forms of contraceptive if their partners are of child-bearing age.\nCitizen or permanent resident of the United States.\n\nExclusion Criteria:\n\nPrior stem cell therapy of any kind.\nInability to lie flat for the duration of intrathecal cell transplantation and/or bone marrow biopsy, or inability to tolerate study procedures for any other reason.\nHistory of autoimmune disease (excluding thyroid disease) myelodysplastic or myeloproliferative disorder, leukemia or lymphoma, whole body irradiation, hip fracture, or severe scoliosis.\nAny unstable clinically significant medical condition other than ALS (e.g., within six months of baseline, had myocardial infarction, angina pectoris, and/or congestive heart failure), treatment with anticoagulants that, in the opinion of the investigator, would compromise the safety of patients.\nAny history of malignancy including any malignancy affecting the central nervous system and melanoma, within the previous 5 years, with the exception of localized skin cancers (with no evidence of metastasis, significant invasion, or re-occurrence within three years of baseline).\nSerum AST or ALT value >3.0 times the upper normal limit.\nSerum creatinine value >2.0 times the upper normal limit.\nPositive test for Hepatitis B, Hepatitis C, HIV.\nCurrent use of immunosuppressant medication or use of such medication within 4 weeks of Screening visit (Visit 1).\nAny history of acquired or inherited immune deficiency syndrome.\nExposure to any other experimental agent (off-label use or investigational) or participation in a clinical trial within 30 days prior to Screening Visit (Visit 1).\nUse of non-invasive ventilation (NIV), diaphragm pacing system or invasive ventilation (tracheostomy).\nAny history of either substance abuse within the past year, or unstable psychiatric disease according to PI judgment.\nPlacement or usage of feeding tube.\nPregnant women or women currently breastfeeding."
                        ],
                        "EnrollmentCount": [
                              "48"
                        ],
                        "EnrollmentType": [
                              "Actual"
                        ],
                        "EventGroupDeathsNumAffected": [],
                        "EventGroupDeathsNumAtRisk": [],
                        "EventGroupDescription": [],
                        "EventGroupId": [],
                        "EventGroupOtherNumAffected": [],
                        "NCTId": [
                              "NCT02017912"
                        ]
                  },
                  {
                        "Rank": 4,
                        "DesignTimePerspective": [],
                        "DesignWhoMasked": [],
                        "DetailedDescription": [
                              "This is an Intermediate-size patient population Expanded Access Protocol (EAP) to provide NurOwn\u00ae (MSC-NTF cells) for eligible ALS participants who completed the BCT-002-US phase 3 ALS clinical trial and have received all three IT treatments.\n\nThe participants will undergo up to three intrathecal (IT) treatments with NurOwn\u00ae (MSC-NTF cells).\n\nIn the first treatment period, the participant received up to three intrathecal (IT) treatments with NurOwn\u00ae (MSC-NTF cells) at T1, T2 and T3 and was followed for 12 weeks after the third treatment.\n\nIn the second treatment period, the participant will receive up to three intrathecal (IT) treatments with NurOwn\u00ae (MSC-NTF cells) every 8 weeks at T4, T5 and T6.\n\nFollowing the last EAP treatment, the participant will be followed for three additional monthly visits (in-person, if feasible, or by telephone call or telemedicine in consideration of the ongoing COVID-19 pandemic) through the final protocol visit, during which the ALSFRS-R and safety assessments will be collected"
                        ],
                        "DispFirstPostDate": [],
                        "DispFirstPostDateType": [],
                        "DispFirstSubmitDate": [],
                        "DispFirstSubmitQCDate": [],
                        "EligibilityCriteria": [
                              "Inclusion Criteria:\n\n1. Participation in the BCT-002-US study, successful completion of all scheduled treatments and follow-up assessments.\n\n2 Able to provide to the Investigator written informed consent regarding the investigational drug, or, as applicable, on whose behalf a legally authorized representative of the participant has provided such consent.\n\n3. Able to safely undergo all study procedures.\n\nExclusion Criteria:\n\nInability to lie flat for the duration of intrathecal cell transplantation and/or bone marrow biopsy, or inability to tolerate treatment procedures for any other reason (lying flat with BiPAP or NIV are not exclusionary).\nHistory of clinically significant autoimmune disease (excluding thyroid disease) myelodysplastic or myeloproliferative disorder, leukemia or lymphoma, whole body irradiation, hip fracture, or severe scoliosis.\nAny unstable clinically significant medical condition other than ALS (e.g., within six months of baseline, had myocardial infarction, angina pectoris, and/or congestive heart failure), treatment with anticoagulants that, in the opinion of the Investigator, would compromise the safety of the participant.\nAny history of malignancy within the previous 5 years, with the exception of non- melanoma localized skin cancers (with no evidence of metastasis, significant invasion, or re-occurrence within three years of baseline).\nCurrent use of immunosuppressant medication or use of such medication within 4 weeks of the pre-treatment visit.\nAny history of acquired or inherited immune deficiency syndrome.\nTracheostomy and/or mechanical ventilation. Feeding tube use, BiPAP or NIV are not exclusionary.\nPregnant women or women currently breastfeeding or unwilling to use effective birth control methods during the treatment (if of childbearing age).\nPositive test result for Hepatitis B virus (HBV; surface antigen (HBsAg) and IgM antibodies to core antigen (IgM anti-HBc)), Hepatitis C virus (HCV), Human Immune deficiency virus (HIV) 1 and 2."
                        ],
                        "EnrollmentCount": [],
                        "EnrollmentType": [],
                        "EventGroupDeathsNumAffected": [],
                        "EventGroupDeathsNumAtRisk": [],
                        "EventGroupDescription": [],
                        "EventGroupId": [],
                        "EventGroupOtherNumAffected": [],
                        "NCTId": [
                              "NCT04681118"
                        ]
                  }
            ]
      }
}